지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한약리학회 The Korean Journal of Physiology & Pharmacology The Korean Journal of Physiology & Pharmacology 제23권 제6호
- 발행연도
- 2019.1
- 수록면
- 459 - 466 (8page)
이용수
초록· 키워드
오류제보하기
Dipeptidyl peptidase (DPP)-4 inhibitors, or gliptins, are a class of oral hypoglycemic drugs that have been widely used as a second-line treatment for type 2 diabetes. Gliptins, which were introduced for clinical use a decade ago, have been shown to be beneficial against nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NASH) in animals and humans. Cenicriviroc (CVC), a dual antagonist of C-C chemokine receptor type 2 and 5, is currently under investigation against NASH and fibrosis. It was previously discovered that evogliptin (EVO) reduces hepatic steatosis in diet-induced obese animals but the effectiveness of EVO on NASH remains unexplored. Here, we compared the effectiveness of EVO and CVC against NASH and fibrosis in mice fed a high-fat and high-fructose diet (HFHF). Biochemical and histological analyses showed that mice fed a HFHF for 20 weeks developed severe hepatic steatosis and inflammation with mild fibrosis. Administration of EVO (0.2% wt/wt) for the last 8 weeks of HFHF feeding significantly reduced hepatic triglyceride accumulation, inflammation, and fibrosis as well as restored insulin sensitivity, as evidenced by lowered plasma insulin levels and the improvement in insulin tolerance test curves. Treatment of mice with CVC (0.1% wt/wt) inhibited hepatic inflammation and fibrogenesis with similar efficacy to that of EVO, without affecting hepatic steatosis. CVC treatment also reduced plasma insulin concentrations, despite no improvement in insulin tolerance. In conclusion, EVO administration efficiently ameliorated the development of NASH and fibrosis in HFHF-fed mice, corroborating its therapeutic potential.
목차
등록된 정보가 없습니다.
참고문헌 (34)
참고문헌 신청
Jung YA / 2014 / Sitagliptin attenuates methionine/cholinedeficient diet-induced steatohepatitis / Diabetes Res Clin Pract 105:47~57
Klein T / 2014 / Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis / Med Mol Morphol 47:137~149
Yilmaz Y / 2012 / Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis / Acta Gastroenterol Belg 75:240~244
배은주 / 2016 / DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control / Archives of Pharmacal Research 39(8):1114~1128
Shirakawa J / 2011 / Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice / Diabetes 60:1246~1257
Klein T / 2014 / Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis / Med Mol Morphol 47:137~149
Yilmaz Y / 2012 / Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis / Acta Gastroenterol Belg 75:240~244
배은주 / 2016 / DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control / Archives of Pharmacal Research 39(8):1114~1128
Shirakawa J / 2011 / Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice / Diabetes 60:1246~1257
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Clinical and Molecular Hepatology
2023 .01
-
비알코올성 지방간 질환의 진단적 평가
대한내과학회지
2020 .10
-
Serologic Biomarkers for Hepatic Fibrosis in Obese Children with Nonalcoholic Steatohepatitis
Pediatric Gastroenterology, Hepatology & Nutrition
2024 .07
-
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
Clinical and Molecular Hepatology
2023 .02
-
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
Clinical and Molecular Hepatology
2023 .02
-
The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018
Endocrinology and Metabolism
2022 .06
-
Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis
Clinical and Molecular Hepatology
2021 .01
-
Pathologic Impact of Insulin Resistance and Sensitivity on the Severity of Liver Histopathology in Pediatric Non-Alcoholic Steatohepatitis
Yonsei Medical Journal
2017 .07
-
Vitamin D Status and Bone Mineral Density in Obese Children with Nonalcoholic Fatty Liver Disease
Journal of Korean Medical Science
2015 .01
-
An application of convolution neural network for analyzing hepatic fibrosis in mouse
한국실험동물학회 학술발표대회 논문집
2022 .01
-
대사증후군을 동반한 비알코올성 지방간염 치험 1례
대한한방내과학회지
2017 .01
-
Low Serum Potassium Levels Associated with Disease Severity in Children with Nonalcoholic Fatty Liver Disease
Pediatric Gastroenterology, Hepatology & Nutrition
2015 .01
-
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Clinical and Molecular Hepatology
2023 .02
-
Histological Analysis of Hepatic Steatosis, Inflammation, and Fibrosis in Ascorbic Acid-Treated Ovariectomized Mice
대한의생명과학회지
2022 .06
-
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
Clinical and Molecular Hepatology
2021 .01
-
Development of non-alcoholic steatohepatitis mouse model
한국실험동물학회 학술발표대회 논문집
2021 .07
-
Fermented ginseng, GBCK25, ameliorates steatosis and inflammation in nonalcoholic steatohepatitis model
Journal of Ginseng Research
2019 .04
-
The Immune Landscape in Nonalcoholic Steatohepatitis
Immune Network
2016 .06
-
Advanced fibrosis leads to overestimation of steatosis with quantitative ultrasound in individuals without hepatic steatosis
ULTRASONOGRAPHY
2024 .03
-
Evaluation of disease severity using multimodal MR imaging in hepatic fibrosis animal model
한국실험동물학회 학술발표대회 논문집
2019 .07
이 논문의 저자 정보
최근 본 자료
댓글(0)
0